Glutamate antagonists and Parkinson's disease: a review of clinical data (Q36867157)

16 August 2017

1 reference

title

Glutamate antagonists and Parkinson's disease: a review of clinical data (English)

1 reference

16 August 2017

1 reference

0 references

Montastruc JL

1

1 reference

16 August 2017

Rascol O

series ordinal

2

1 reference

16 August 2017

Senard JM

series ordinal

3

1 reference

16 August 2017

publication date

1 July 1997

1 reference

Neuroscience & Biobehavioral Reviews

16 August 2017

published in

1 reference

16 August 2017

volume

21

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

477-480

1 reference

Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

Dextromethorphan. An overview of safety issues

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

Dextromethorphan and parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

Ifenprodil and SL 82.0715 potently inhibit binding of [3H](+)-3-PPP to sigma binding sites in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats?--case of amantadine and memantine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

Excitatory amino acid antagonists and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

The neuroprotective properties of ifenprodil, a novel NMDA receptor antagonist, in neuronal cell culture toxicity studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

N-Methyl-d-Aspartate Antagonists in the Treatment of Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

Excitatory amino acid neurotoxicity and neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

Current status of dopamine agonists in Parkinson's disease management

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

Neuroprotection in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

The neuroprotective effects of dextromethorphan on guinea pig-derived hippocampal slices during hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

The NMDA receptor complex

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

Sites for Antagonism on the N-Methyl-D-Aspartate Receptor Channel Complex

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2896%2900035-8

7 January 2021

10.1016/S0149-7634(96)00035-8

Identifiers

DOI

1 reference

16 August 2017

1 reference